Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma

Fig. 5

Validation of proteomic data of NOVA1 in low-grade astrocytoma and oligodendroglioma patient samples. a qRT-PCR of NOVA1 gene in astrocytoma grade II (AST II) and oligodendroglioma (OLI II and OLI III). Data analyses were normalized by same set of housekeeping genes: HPRT, GUSB, TBP and Mann Whitney statistical test. b Western blot of NOVA1 in individual astrocytoma and oligodendroglioma patient samples (n = 3 and 4); c Immunohistochemistry (IHC) of NOVA1 in astrocytomas and oligodendrogliomas. a Non neoplastic (NN); b Pilocytic astrocytomas (AST I); c Diffuse astrocytoma (AST II); d Anaplastic astrocytomas (AST III), and e Glioblastoma (GBM, 200×) f Glioblastoma (GBM, 400×); g Oligodendroglioma II and h Oligodendroglioma III. i Graphical plot of IHC relative expression of NOVA1 distribution between nucleus and cytoplasm

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us